ACKNOWLEDGMENT TO REVIEWERS OPEN ACCESS

Neurology® Genetics Acknowledgment to Reviewers

Stefan Pulst, MD, Dr med, FAAN

Neurol Genet 2022;8:e671. doi:10.1212/NXG.0000000000000671

We wish to acknowledge the individuals who have completed reviews for the journal over the course of 2021. Your thoughtful comments and insights are tremendously helpful, highly appreciated, and imperative for excellence in the field of neurogenetics. We are also grateful for your cooperation in returning reviews in a timely manner. Please find the guidelines for reviewing articles on the *Neurology: Genetics* website at ng.neurology.org/. This page provides information on expectations of reviewers regarding confidentiality, timeliness, and reviewer conflicts of interest; it also provides instructions for formatting the comments to editors and authors to enable the most effective communication with authors.

We welcome the involvement of junior faculty and trainees of diverse backgrounds in the review process. Please disclose their participation and acknowledge their contributions when you return your review.

Please email ngjournal@neurology.org if you are interested in completing more reviews for *Neurology: Genetics* or if you have never reviewed for the journal but are interested in doing so. Include a description of your credentials and expertise in the areas in which you are qualified to review. We look forward to hearing from you!

The reviewers listed below with 1 asterisk have reviewed 5 or more articles in 2021. This list includes those reviewers who returned a review or reviews of initial submissions (re-reviews of the same article are not included).

Jan O. Aasly
Justin R. Abbatemarco
Cigdem Inan Akman
Juliann Allred
Danielle M. Andrade
Juan Pablo Appendino
Ping-Yee Billie Au
Nadia Bahi-Buisson
Mark K Bakker
Anna Bersano
Thomas D. Bird
Craig Blackstone
Sylvia M. Boesch
Francois Bolduc
Joshua Bonkowsky
Stephanie Borel
Felippe Borlot
Nicola Brunetti-Pierri
Lydie Burglen
Franca Cambi
Gaetano Cantalupo
Greg Cary
Stacey Lynn Clardy
Royce Clifford
Giulia Coarelli
Frederic Darios
Stefano D'Arrigo
Han-Xiang Deng*
Chantal Depondt
Orrin Devinsky
Jacopo C. DiFrancesco
James J. Dowling
Luc Dupuis
Antoine Duquette
Andreas Eigentler
Claire Ewenczyk
James Fang
Alfonso Fasano
Alessandro Filla
Brent L. Fogel
Ana Catarina Fonseca
Emily Forbes
Marcondes C. França Jr.
Gary M. Franklin
Pietro Fratta
Shinsuke Fujioka
Yoshiaki Furukawa
Partha S. Ghosh
David Gloss
Cyril Goizet
Alica M. Goldman
Kathleen M Gorman
David Grabli
Andrea L. Gropman
Renzo Guerrini
David H. Gutmann
Harald J. Hampel
Peter Hedera
Solveig Heide
Rita Horvath
Suman Jayadev
Peter B. Kang
Masahisa Katsuno
Mohamed Kazamel
Christopher J. Klein
Gabor G. Kovacs
Hubertus Kremer
Martin Krenn
Michael C. Kruer
Eugene C. Lai
Anthony E. Lang
Holger Lerche
Suzanne Lesage
Ariel Levy
Robert Listernick
Michelangelo Mancuso
Andrea Martinuzzi
Alberto Maud
Jean-Loup Mereaux
Albee Messing
Paolo Moretti
Kenneth Alexis Myers
Stefan Nicolau*
Karen Nuytemans
Saskia A.J. Lesnik Oberstein
Heather E Olson
Osamu Onodera
Coro Paisan-Ruiz
Davide Pareyson
Piero Pavone
Gerald Pfeffer*
Lance Pflieger
Anna L.R. Pinto
Roser Pons
Christos Proukakis
Ros C.M. Quinlivan
Catarina M. Quinzii
Wendy Herlihy Raskind
Mary M. Reilly
M. Elizabeth Ross
Mario Sabatelli
Rachel J. Saunders-Pullman
Barbara Scelsa
Susanne A. Schneider
Daniel Scoles
Duygu Selcen
Serenella Servidei*
Joshua M. Shulman

Disclosure

Scientific Advisory Boards: National Ataxia Foundation, Medical Research Advisory Board Hertie Institute for Brain Science, University of Tuebingen. Editorial Boards: Nature Clinical Practice Neurology; Editor: *Neurology® Genetics*. Patents: Nucleic acids encoding ataxin-2 binding proteins; Nucleic acid encoding Schwannomin-binding-proteins and products related thereto; Transgenic mouse expressing a polynucleotide encoding a human ataxin-2 polypeptide; Methods of detecting spinocerebellar ataxia-2 nucleic acids; Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto; Schwannomin-binding-proteins; Compositions and methods for spinocerebellar ataxia; Methods For Modulating Ataxin2 Expression. Publishing Royalties: The Ataxias (Churchill Livingston, 2007), Genetics in Neurology (ANN Press, 2005), Genetics of Movement Disorders (Academic Press, 2003), Neurogenetics (Oxford University Press, 2000), Molecular Genetic Testing in Neurology, 2nd - 5th (AAN Press, 1996). Research Support, Government Entities: 2014–2021 National Institutes of Health (R37NS33123): Spinocerebellar ataxia type 2: gene and gene product. 9/30/14–6/30/2021. (Principal Investigator). 2018–2020 Harrington Discovery Institute Harrington Rare Disease Award: Development of a therapeutic for SCA2 and other rare neurodegenerative diseases. 3/1/18–2/28/20. Co-Investigator (Principal Investigator: D. Scoles) 2014–2021 National Institutes of Health Senator Jacob Javits Merit Award (R37 NS033123): Spinocerebellar ataxia type 2: gene and gene product. 10/1/14–6/30/21. Principal Investigator 2017–2020 National Institutes of Health (R21 NS104799-01): Deep cerebellar stimulation to treat degenerative cerebellar ataxia. 9/1/17–8/31/20. Principal Investigator 2017–2022 National Institutes of Health (R01 NS097903): RNA granules in cerebellar neurodegeneration. 4/1/17–3/31/22. Co-Investigator (Principal Investigator: D. Scoles) 2018–2021 National Institute of Neurological Disorders and Stroke (U01 NS103883): Antisense Oligonucleotides for treating spinocerebellar ataxia type 2. 2/15/18–1/31/21. Principal Investigator (with D. Scoles) 2018–2023 National Institute of Neurological Disorders and Stroke (U01 NS104326): Clinical Trial readiness for SCA1 and SCA3. 1/1/18–12/31/2023. Site Investigator (Principal Investigator: T. Ashizawa) 2018–2020 National Institute of Neurological Disorders and Stroke (R21NS103009): Characterization of ATXN2 as a target for ALS in SCA2 motor neurons. 7/1/18–6/30/21. Principal Investigator. 2019–2024 National Institute of Neurological Disorders and Stroke (R01 NS085054): Identifying symptomatic and neuroprotective strategies for cerebellar ataxia. 4/15/2019–3/31/2024. Site Investigator (Principal Investigator: V. Shakkottai) 2020–2023 CYDAN: SCA1 and SCA2 Studies With Cck1 Receptor Agonist. 1/1/2020–12/31/23. Principal Investigator: License fee payments, Technology or Inventions: University of Utah (license for invention & technologies). Royalty Payments, Technology or Inventions: University of Utah. Go to Neurology.org/NG for full disclosures.

Neurology® Genetics Acknowledgment to Reviewers

Stefan Pulst

Neurol Genet 2022;8;
DOI 10.1212/NXG.0000000000000671